{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:21:09Z","timestamp":1772050869090,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82172635"],"award-info":[{"award-number":["No. 82172635"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82203628"],"award-info":[{"award-number":["No. 82203628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying <jats:italic>EGFR<\/jats:italic> mutation with or without concurrent mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This phase 2, single-arm, multicenter trial (ClinicalTrials.gov NCT03736837) was performed at five hospitals in China from December 2018 to November 2020. Non-squamous NSCLC cases with EGFR-sensitizing mutations were treated with anlotinib and icotinib. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty participants were enrolled, including 31 (52%) and 29 (48%) with concurrent mutations and pathogenic concurrent mutations, respectively. The median follow-up was 26.9 (range, 15.0-38.9) months. ORR and DCR were 68.5% and 98.2%, respectively. Median PFS was 15.1 (95%CI: 12.6\u201317.6) months which met the primary endpoint, median DoR was 13.5 (95%CI: 10.0-17.1) months, and median OS was 30.0 (95%CI: 25.5\u201334.5) months. Median PFS and OS in patients with pathogenic concurrent mutations were 15.6 (95%CI: 12.5\u201318.7) months and not reached (95%CI: 17.46 months to not reached), respectively. All patients experienced TRAEs, including 26 (43%) and 1 (1.7%) who had grade\u2009\u2265\u20093 and serious treatment-related adverse events (TRAEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anlotinib combined with icotinib was effective and well-tolerated as a first-line treatment option for EGFR mutation-positive advanced NSCLC with or without concurrent mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier: NCT03736837.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-023-01823-w","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T09:01:33Z","timestamp":1691226093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study"],"prefix":"10.1186","volume":"22","author":[{"given":"Linlin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoting","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"issue":"2","key":"1823_CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","volume":"10","author":"M Shea","year":"2016","unstructured":"Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10(2):113\u201329.","journal-title":"Ther Adv Respir Dis"},{"issue":"suppl 5","key":"1823_CR2","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1\u2013v27.","journal-title":"Ann Oncol"},{"issue":"5 Suppl","key":"1823_CR3","doi-asserted-by":"crossref","first-page":"e121S","DOI":"10.1378\/chest.12-2352","volume":"143","author":"DE Ost","year":"2013","unstructured":"Ost DE, Jim Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e121S\u2013e41S.","journal-title":"Chest"},{"issue":"27","key":"1823_CR4","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1200\/JCO.2013.49.8782","volume":"31","author":"CJ Langer","year":"2013","unstructured":"Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31(27):3303\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1823_CR5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530.","journal-title":"J Natl Compr Canc Netw"},{"key":"1823_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ebiom.2019.03.037","volume":"42","author":"R Rosell","year":"2019","unstructured":"Rosell R, Karachaliou N. Co-mutations in EGFR driven non-small cell lung cancer. EBioMedicine. 2019;42:18\u20139.","journal-title":"EBioMedicine"},{"key":"1823_CR7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ebiom.2019.03.023","volume":"42","author":"M Chen","year":"2019","unstructured":"Chen M, Xu Y, Zhao J, Zhong W, Zhang L, Bi Y, et al. Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive Non-Small Cell Lung Cancer. EBioMedicine. 2019;42:304\u201310.","journal-title":"EBioMedicine"},{"issue":"9","key":"1823_CR8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Cheng Y, An T, Gao H, Wang K, Zhou Q, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6(9):681\u201390.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1823_CR9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2018.0049","volume":"4","author":"S Hong","year":"2018","unstructured":"Hong S, Gao F, Fu S, Wang Y, Fang W, Huang Y, et al. Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(5):739\u201342.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1823_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"3","key":"1823_CR11","first-page":"217","volume":"4","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Yamada Y. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. Transl Lung Cancer Res. 2015;4(3):217\u20139.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"1823_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625\u201335.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1823_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40264-021-01127-2","volume":"45","author":"E Nadal","year":"2022","unstructured":"Nadal E, Horinouchi H, Shih JY, Nakagawa K, Reck M, Garon EB, et al. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in patients with untreated, epidermal growth factor receptor Mutation-Positive, metastatic non-small-cell Lung Cancer: Safety Profile and Manageability. Drug Saf. 2022;45(1):45\u201364.","journal-title":"Drug Saf"},{"issue":"12","key":"1823_CR14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655\u201369.","journal-title":"Lancet Oncol"},{"key":"1823_CR15","doi-asserted-by":"crossref","first-page":"100378","DOI":"10.1016\/j.ctarc.2021.100378","volume":"27","author":"S Ponce Aix","year":"2021","unstructured":"Ponce Aix S, Novello S, Garon EB, Nakagawa K, Nadal E, Moro-Sibilot D, et al. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe\/United States subset analysis. Cancer Treat Res Commun. 2021;27:100378.","journal-title":"Cancer Treat Res Commun"},{"issue":"9","key":"1823_CR16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","volume":"16","author":"H Zhao","year":"2021","unstructured":"Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, et al. Apatinib Plus Gefitinib as First-Line treatment in Advanced EGFR-Mutant NSCLC: the Phase III ACTIVE Study (CTONG1706). J Thorac Oncol. 2021;16(9):1533\u201346.","journal-title":"J Thorac Oncol"},{"key":"1823_CR17","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.2147\/CMAR.S246000","volume":"12","author":"K Zhang","year":"2020","unstructured":"Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S, et al. Efficacy and safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: a real-world study. Cancer Manag Res. 2020;12:3409\u201317.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1823_CR18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2018.5526","volume":"5","author":"XZ Chen","year":"2019","unstructured":"Chen XZ. Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China. JAMA Oncol. 2019;5(1):116\u20137.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1823_CR19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced Non-Small Cell Lung Cancer: the ALTER 0303 phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1569\u201375.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1823_CR20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/ng.3703","volume":"48","author":"KA Jagadeesh","year":"2016","unstructured":"Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet. 2016;48(12):1581\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"1823_CR21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12881-019-0873-0","volume":"20","author":"X Kong","year":"2019","unstructured":"Kong X, Zhong X, Liu L, Cui S, Yang Y, Kong L. Genetic analysis of 1051 chinese families with Duchenne\/Becker muscular dystrophy. BMC Med Genet. 2019;20(1):139.","journal-title":"BMC Med Genet"},{"issue":"4","key":"1823_CR22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248\u20139.","journal-title":"Nat Methods"},{"issue":"14","key":"1823_CR23","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-19-3976","volume":"26","author":"K Zhang","year":"2020","unstructured":"Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G, et al. Identification of deleterious NOTCH mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC. Clin Cancer Res. 2020;26(14):3649\u201361.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1823_CR24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","volume":"11","author":"JM Schwarz","year":"2014","unstructured":"Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361\u20132.","journal-title":"Nat Methods"},{"issue":"8","key":"1823_CR25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nmeth0810-575","volume":"7","author":"JM Schwarz","year":"2010","unstructured":"Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575\u20136.","journal-title":"Nat Methods"},{"issue":"10","key":"1823_CR26","doi-asserted-by":"crossref","first-page":"e46688","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE. 2012;7(10):e46688.","journal-title":"PLoS ONE"},{"issue":"1","key":"1823_CR27","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","volume":"12","author":"SY Liu","year":"2021","unstructured":"Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, et al. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. 2021;12(1):6450.","journal-title":"Nat Commun"},{"issue":"3","key":"1823_CR28","first-page":"3159","volume":"18","author":"Y Liu","year":"2019","unstructured":"Liu Y, Xu F, Wang Y, Wu Q, Wang B, Yao Y, et al. Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. Oncol Lett. 2019;18(3):3159\u201369.","journal-title":"Oncol Lett"},{"key":"1823_CR29","doi-asserted-by":"crossref","unstructured":"Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S et al. Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2018;2018.","DOI":"10.1200\/PO.18.00107"},{"issue":"9","key":"1823_CR30","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, et al. Impact of TP53 mutations on Outcome in EGFR-Mutated Patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23(9):2195\u2013202.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1823_CR31","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552\u201361.","journal-title":"N Engl J Med"},{"issue":"15S","key":"1823_CR32","doi-asserted-by":"crossref","first-page":"Abstract9041","DOI":"10.1200\/JCO.2016.34.15_suppl.9041","volume":"34","author":"YK Shi","year":"2016","unstructured":"Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatine\/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE). J Clin Oncol. 2016;34(15S):Abstract9041.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1823_CR33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","volume":"14","author":"BC Cho","year":"2019","unstructured":"Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, et al. Osimertinib versus Standard of Care EGFR TKI as First-Line treatment in patients with EGFRm Advanced NSCLC: FLAURA asian subset. J Thorac Oncol. 2019;14(1):99\u201310634.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1823_CR34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, et al. Osimertinib Versus Comparator EGFR TKI as First-Line treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, a Randomized Study. Target Oncol. 2021;16(2):165\u201376.","journal-title":"Target Oncol"},{"issue":"19","key":"1823_CR35","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1111\/1759-7714.14141","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang C, Cao H, Cui Y, Jin S, Gao W, Huang C, et al. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2021;12(19):2574\u201384.","journal-title":"Thorac Cancer"},{"issue":"3","key":"1823_CR36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jtho.2016.09.001","volume":"12","author":"MB Barnet","year":"2017","unstructured":"Barnet MB, O\u2019Toole S, Horvath LG, Selinger C, Yu B, Ng CC, et al. EGFR-Co-Mutated Advanced NSCLC and Response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2017;12(3):585\u201390.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1823_CR37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495\u2013509.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1823_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tlcr-21-754","volume":"11","author":"J Roeper","year":"2022","unstructured":"Roeper J, Christopoulos P, Falk M, Heukamp LC, Tiemann M, Stenzinger A, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res. 2022;11(1):4\u201313.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"1823_CR39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an Ensemble Method for Predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877\u201385.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1823_CR40","doi-asserted-by":"crossref","first-page":"10281","DOI":"10.1002\/jcb.28312","volume":"120","author":"M Amir","year":"2019","unstructured":"Amir M, Kumar V, Mohammad T, Dohare R, Hussain A, Rehman MT, et al. Investigation of deleterious effects of nsSNPs in the POT1 gene: a structural genomics-based approach to understand the mechanism of cancer development. J Cell Biochem. 2019;120(6):10281\u201394.","journal-title":"J Cell Biochem"},{"issue":"6","key":"1823_CR41","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/ijc.31825","volume":"144","author":"F Ye","year":"2019","unstructured":"Ye F, Gao H, Xiao L, Zuo Z, Liu Y, Zhao Q, et al. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma. Int J Cancer. 2019;144(6):1321\u201330.","journal-title":"Int J Cancer"},{"key":"1823_CR42","doi-asserted-by":"crossref","unstructured":"Caporali S, Didona B, Paradisi M, Mauriello A, Campione E, Falconi M et al. Post zygotic, somatic, deletion in KERATIN 1 V1 domain generates structural alteration of the K1\/K10 Dimer, producing a Monolateral Palmar Epidermolytic Nevus. Int J Mol Sci. 2021;22(13).","DOI":"10.3390\/ijms22136901"},{"key":"1823_CR43","doi-asserted-by":"crossref","unstructured":"Slater EP, Wilke LM, Bohm LB, Strauch K, Lutz M, Gercke N et al. Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer. J Pers Med. 2021;11(7).","DOI":"10.3390\/jpm11070631"},{"issue":"17","key":"1823_CR44","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","volume":"20","author":"MA Molina-Vila","year":"2014","unstructured":"Molina-Vila MA, Bertran-Alamillo J, Gasco A, Mayo-de-las-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2014;20(17):4647\u201359.","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01823-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:35:48Z","timestamp":1700573748000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01823-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1823"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01823-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical protocol was approved by the respective institutional review boards and ethics committees. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}